{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:41:20Z","timestamp":1788496880975,"version":"build-2803163510"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejmech.2025.117700","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T15:13:15Z","timestamp":1746457995000},"page":"117700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Design and synthetic approaches to thalidomide based small molecule degraders"],"prefix":"10.1016","volume":"293","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1480-4785","authenticated-orcid":false,"given":"Ajeet","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4012-1072","authenticated-orcid":false,"given":"Gulshan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7563-6678","authenticated-orcid":false,"given":"Nidhi","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3308-615X","authenticated-orcid":false,"given":"Priya Ranjan","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117700_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s002280100320","article-title":"Clinical pharmacology of thalidomide","volume":"57","author":"Eriksson","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117700_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/tera.1420380303","article-title":"A short history of thalidomide embryopathy","volume":"38","author":"Lenz","year":"1988","journal-title":"Teratology"},{"key":"10.1016\/j.ejmech.2025.117700_bib3","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2025.117700_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2183\/pjab.96.016","article-title":"Molecular mechanisms of thalidomide and its derivatives","volume":"96","author":"Ito","year":"2020","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"10.1016\/j.ejmech.2025.117700_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113749","article-title":"Developments of CRBN-Based PROTACs as potential therapeutic agents","volume":"225","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib6","first-page":"287","article-title":"What is the functional role of the thalidomide binding protein cereblon?","volume":"2","author":"Chang","year":"2011","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117700_bib7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/leu.2013.315","article-title":"Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy","volume":"28","author":"Thakurta","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117700_bib8","doi-asserted-by":"crossref","first-page":"11615","DOI":"10.1021\/acs.jmedchem.0c00793","article-title":"Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications","volume":"63","author":"Goracci","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib9","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acschembio.6b01068","article-title":"Proteolysis-targeting chimeras: induced protein degradation as a therapeutic strategy","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117700_bib10","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.117700_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117700_bib12","first-page":"2366","article-title":"The novel mechanism of lenalidomide activity, blood","volume":"126","author":"Fink","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2025.117700_bib13","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s41589-019-0366-7","article-title":"p63 is a cereblon substrate involved in thalidomide teratogenicity","volume":"15","author":"Asatsuma-Okumura","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117700_bib14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nature14628","article-title":"Another action of a thalidomide derivative","volume":"523","author":"Ito","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117700_bib15","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117700_bib16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del (5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117700_bib17","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.117700_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.117700_bib19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2025.117700_bib20","doi-asserted-by":"crossref","first-page":"15282","DOI":"10.1021\/acs.jmedchem.2c01218","article-title":"A versatile and sustainable multicomponent platform for the synthesis of protein degraders: proof-Of-concept application to BRD4-Degrading PROTACs","volume":"65","author":"Bhela","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib21","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1126\/science.1249830","article-title":"A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes","volume":"346","author":"Baud","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117700_bib22","doi-asserted-by":"crossref","first-page":"11637","DOI":"10.1021\/acs.jmedchem.1c00958","article-title":"Structure-guided design of a \u201cbump-and-hole\u201d bromodomain-based degradation tag","volume":"64","author":"Nowak","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0092-8674(02)00827-9","article-title":"IRAK-M is a negative regulator of toll-like receptor signaling","volume":"110","author":"Kobayashi","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117700_bib24","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1021\/acs.jmedchem.0c01125","article-title":"Discovery of proteolysis-targeting chimera molecules that selectively degrade the IRAK3 pseudokinase","volume":"63","author":"Degorce","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib25","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-R","article-title":"The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation","volume":"69","author":"Momand","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117700_bib26","first-page":"993","article-title":"An introduction","volume":"1","author":"Iwakuma","year":"2003","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117700_bib27","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1021\/acs.jmedchem.6b01665","volume":"60","author":"Aguilar","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib28","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a potent and selective p53\u2013MDM2 inhibitor in clinical development","volume":"56","author":"Ding","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib29","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","article-title":"Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression","volume":"62","author":"Li","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib30","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1021\/acs.jmedchem.9b00846","article-title":"Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib31","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","article-title":"Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib32","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.tibs.2019.04.005","article-title":"Emerging roles for polycomb-group proteins in stem cells and cancer","volume":"44","author":"Chan","year":"2019","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2025.117700_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117700_bib34","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1021\/ml3003346","article-title":"Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2","volume":"3","author":"Verma","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117700_bib35","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117700_bib36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117700_bib37","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-09-0013","article-title":"DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation","volume":"8","author":"Miranda","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117700_bib38","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","article-title":"Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2567.2005.02091.x","article-title":"Signal transducer and activator of transcription (STAT) signalling and T\u2010cell lymphomas","volume":"114","author":"Mitchell","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.ejmech.2025.117700_bib40","first-page":"803","article-title":"Jak-stat pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"257","author":"Darnel","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117700_bib41","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/ijms19061591","article-title":"Structural biology of STAT3 and its implications for anticancer therapies development","volume":"19","author":"Sgrignani","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117700_bib42","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1158\/0008-5472.CAN-10-0736","article-title":"Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells","volume":"70","author":"Herrmann","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejmech.2025.117700_bib43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.coi.2008.03.010","article-title":"Role of Stat3 in suppressing anti-tumor immunity","volume":"20","author":"Kortylewski","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ejmech.2025.117700_bib44","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1172\/JCI35213","article-title":"Stat3 mediates myeloid cell\u2013dependent tumor angiogenesis in mice","volume":"118","author":"Kujawski","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.117700_bib45","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1021\/acs.jmedchem.1c00629","article-title":"Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation","volume":"64","author":"Dong","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib46","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.117700_bib47","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.it.2015.02.003","article-title":"The STING pathway and the T cell-inflamed tumor microenvironment R","volume":"36","author":"Corrales","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ejmech.2025.117700_bib48","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","article-title":"STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity","volume":"112","author":"Demaria","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2025.117700_bib49","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","article-title":"The cGAS\u2013STING pathway as a therapeutic target in inflammatory diseases","volume":"21","author":"Decout","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.117700_bib50","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1016\/j.celrep.2018.11.097","article-title":"The cyclopeptide astin C specifically inhibits the innate immune CDN sensor STING","volume":"25","author":"Li","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejmech.2025.117700_bib51","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2105465118","article-title":"STING Inhibitors Target the Cyclic Dinucleotide Binding Pocket","volume":"118","author":"Hong","year":"2021","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.ejmech.2025.117700_bib52","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41586-018-0287-8","article-title":"Targeting STING with covalent small-molecule inhibitors","volume":"559","author":"Haag","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117700_bib53","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cell.2020.07.001","article-title":"An activity-guided map of electrophile-cysteine interactions in primary human T cells","volume":"182","author":"Vinogradova","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117700_bib54","doi-asserted-by":"crossref","first-page":"E7768","DOI":"10.1073\/pnas.1806239115","article-title":"Nitro-Fatty Acids are Formed in Response to Virus Infection and are Potent Inhibitors of STING Palmitoylation and Signaling","volume":"115","author":"Hansen","year":"2018","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.ejmech.2025.117700_bib55","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1021\/acs.jmedchem.1c01948","article-title":"Novel CRBN-recruiting proteolysis-targeting chimeras as degraders of stimulator of interferon genes with in vivo anti-inflammatory efficacy","volume":"65","author":"Liu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib56","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2003-030261","article-title":"Expression and degradation of androgen receptor: mechanism and clinical implication","volume":"88","author":"Lee","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2025.117700_bib57","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.117700_bib58","doi-asserted-by":"crossref","first-page":"12831","DOI":"10.1021\/acs.jmedchem.1c00882","article-title":"Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer","volume":"64","author":"Han","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib59","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1021\/acs.jmedchem.0c01897","article-title":"Discovery of a napabucasin PROTAC as an effective degrader of the E3 ligase ZFP91","volume":"64","author":"Hanafi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib60","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.3390\/molecules28155678","article-title":"The anticancer effect of napabucasin (BBI608), a natural naphthoquinone","volume":"28","author":"Shao","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117700_bib61","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1073\/pnas.1424171112","article-title":"Suppression of cancer relapse and metastasis by inhibiting cancer stemness","volume":"112","author":"Li","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2025.117700_bib62","unstructured":"C. biolabs, Cliptacs, in."},{"key":"10.1016\/j.ejmech.2025.117700_bib63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s43586-021-00028-z","volume":"1","author":"Scinto","year":"2021","journal-title":"Bioorthogonal chemistry, Nature Rev. Methods Prim."},{"key":"10.1016\/j.ejmech.2025.117700_bib64","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1002\/ange.201200994","article-title":"Bioorthogonal imaging of Aurora kinase A in live cells","volume":"124","author":"Yang","year":"2012","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib65","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/acscentsci.6b00280","article-title":"Protein degradation by in-cell self-assembly of proteolysis targeting chimeras","volume":"2","author":"Lebraud","year":"2016","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2025.117700_bib66","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1021\/acs.jmedchem.0c01313","article-title":"Identification of potent, selective, and orally bioavailable small-molecule GSPT1\/2 degraders from a focused library of cereblon modulators","volume":"64","author":"Nishiguchi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib67","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/acs.jmedchem.9b00455","article-title":"From inhibition to degradation: targeting the antiapoptotic protein myeloid cell leukemia 1 (MCL1)","volume":"62","author":"Papatzimas","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrm3293","article-title":"Sirtuins as regulators of metabolism and healthspan","volume":"13","author":"Houtkooper","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117700_bib69","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/acs.jmedchem.6b01872","article-title":"Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals)","volume":"61","author":"Schiedel","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113341","article-title":"Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders","volume":"218","author":"Yang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib71","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1039\/C8CC08716D","article-title":"Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC)","volume":"55","author":"Krajcovicova","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.117700_bib72","doi-asserted-by":"crossref","first-page":"12273","DOI":"10.1021\/acs.jmedchem.1c00901","article-title":"Folate-guided protein degradation by immunomodulatory imide drug-based molecular glues and proteolysis targeting chimeras","volume":"64","author":"Chen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib73","article-title":"Studying early structural changes in SOS1 mediated KRAS activation mechanism","volume":"7","author":"Bhadhadhara","year":"2024","journal-title":"Curr. Res. Struct. Biol."},{"key":"10.1016\/j.ejmech.2025.117700_bib74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cbpa.2021.02.014","article-title":"Targeting son of sevenless 1: the pacemaker of KRAS","volume":"62","author":"Kessler","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117700_bib75","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1038\/s41467-023-41583-1","article-title":"Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma","volume":"14","author":"Baltan\u00e1s","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117700_bib76","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.2c01300","article-title":"Development of SOS1 inhibitor-based degraders to target KRAS-mutant colorectal cancer","author":"Bian","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib77","doi-asserted-by":"crossref","first-page":"14822","DOI":"10.1021\/acs.jmedchem.1c01350","article-title":"Discovery of potent and selective CDK9 degraders for targeting transcription regulation in triple-negative breast cancer","volume":"64","author":"Wei","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib78","doi-asserted-by":"crossref","first-page":"15642","DOI":"10.1021\/acs.jmedchem.2c00771","article-title":"Identification and characterization of a novel indoleamine 2, 3-dioxygenase 1 protein degrader for glioblastoma","volume":"65","author":"Bollu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117700_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.800630","article-title":"Indoleamine 2, 3-dioxygenase 1: a promising therapeutic target in malignant tumor","volume":"12","author":"Song","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.117700_bib81","doi-asserted-by":"crossref","first-page":"11012","DOI":"10.1021\/acs.jmedchem.0c00821","article-title":"Discovery of SK-575 as a highly potent and efficacious proteolysis-targeting chimera degrader of PARP1 for treating cancers","volume":"63","author":"Cao","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib82","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/j.clml.2021.09.002","article-title":"FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myeloid leukemia","volume":"22","author":"Novatcheva","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejmech.2025.117700_bib83","doi-asserted-by":"crossref","first-page":"16497","DOI":"10.1021\/acs.jmedchem.1c00996","article-title":"Proteolysis-targeting chimera (PROTAC) modification of Dovitinib enhances the antiproliferative effect against FLT3-ITD-positive acute myeloid leukemia cells","volume":"64","author":"Cao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib84","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/acs.jmedchem.6b01816","article-title":"Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression","volume":"61","author":"Zhou","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib85","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1074\/jbc.272.13.8482","article-title":"Identification of pirin, a novel highly conserved nuclear protein","volume":"272","author":"Wendler","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib86","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/acs.jmedchem.6b01055","article-title":"Discovery of a chemical probe bisamide (CCT251236): an orally bioavailable efficacious pirin ligand from a heat shock transcription factor 1 (HSF1) phenotypic screen","volume":"60","author":"Cheeseman","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib87","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1021\/acs.jmedchem.7b01406","article-title":"Demonstrating in-cell target engagement using a pirin protein degradation probe (CCT367766)","volume":"61","author":"Chessum","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib88","doi-asserted-by":"crossref","first-page":"14562","DOI":"10.1021\/acs.jmedchem.0c01342","article-title":"Discovery of first-in-class potent and selective tropomyosin receptor kinase degraders","volume":"63","author":"Chen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib89","doi-asserted-by":"crossref","first-page":"10611","DOI":"10.1021\/acs.jmedchem.2c00807","article-title":"Discovery of a first-in-class degrader for nuclear receptor binding SET domain protein 2 (NSD2) and Ikaros\/Aiolos","volume":"65","author":"Meng","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib90","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1021\/acs.jmedchem.9b00516","article-title":"Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity","volume":"62","author":"Wu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib91","doi-asserted-by":"crossref","first-page":"13487","DOI":"10.1021\/acs.jmedchem.1c00900","article-title":"Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer","volume":"64","author":"Xiang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib92","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1016\/j.biomaterials.2013.07.100","article-title":"Epidermal growth factor receptor targeting in cancer: a review of trends and strategies","volume":"34","author":"Yewale","year":"2013","journal-title":"Biomater"},{"key":"10.1016\/j.ejmech.2025.117700_bib93","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117700_bib94","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.2c00345","article-title":"Exploring degradation of mutant and wild-type epidermal growth factor receptors induced by proteolysis-targeting chimeras","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib95","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1021\/acs.jmedchem.9b02083","article-title":"Discovery of selective small molecule degraders of BRAF-V600E","volume":"63","author":"Han","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib96","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1021\/acs.jmedchem.1c01768","article-title":"Discovery of the first examples of threonine tyrosine kinase PROTAC degraders","volume":"65","author":"Lu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib97","doi-asserted-by":"crossref","first-page":"11066","DOI":"10.1021\/acs.jmedchem.2c00384","article-title":"Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib98","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib99","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","article-title":"CC-90009: a cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia","volume":"64","author":"Hansen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib100","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1021\/acs.jmedchem.6b01911","article-title":"Protein degradation via CRL4CRBN ubiquitin ligase: discovery and structure\u2013activity relationships of novel glutarimide analogs that promote degradation of aiolos and\/or GSPT1","volume":"61","author":"Hansen","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib101","doi-asserted-by":"crossref","first-page":"17098","DOI":"10.1021\/acs.jmedchem.1c01069","article-title":"Targeting of the FOXM1 oncoprotein by E3 ligase-assisted degradation","volume":"64","author":"Luo","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib102","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1158\/0008-5472.CAN-16-3566","article-title":"FOXM1 in cancer: interactions and vulnerabilities","volume":"77","author":"Gartel","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117700_bib103","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.3390\/cancers12092677","article-title":"Suppression of tumor growth, metastasis, and signaling pathways by reducing FOXM1 activity in triple negative breast cancer","volume":"12","author":"Dey","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117700_bib104","series-title":"Advances in Inhibitors of Potential Tumor Target FOXM1","first-page":"809","author":"Han","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117700_bib105","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.166698","article-title":"RNF112-mediated FOXM1 ubiquitination suppresses the proliferation and invasion of gastric cancer","volume":"8","author":"Zhang","year":"2023","journal-title":"JCI insight"},{"key":"10.1016\/j.ejmech.2025.117700_bib106","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1039\/c2cc30831b","article-title":"Chemical methods for degradation of target proteins using designed light-activatable organic molecules","volume":"48","author":"Tanimoto","year":"2012","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.117700_bib107","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1002\/cbic.202000113","article-title":"Optochemical control of protein degradation","volume":"21","author":"Wu","year":"2020","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.117700_bib108","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acscentsci.9b00713","article-title":"Reversible spatiotemporal control of induced protein degradation by bistable PhotoPROTACs","volume":"5","author":"Pfaff","year":"2019","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2025.117700_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202314791","article-title":"Optical control of proteasomal protein degradation with a photoswitchable lipopeptide","volume":"63","author":"Morstein","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2025.117700_bib110","series-title":"Stimuli-Responsive Materials for Biomedical Applications","first-page":"101","article-title":"Light responsive materials: properties, design, and applications","author":"Sahoo","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117700_bib111","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-induced protein degradation with photocaged PROTACs","volume":"141","author":"Xue","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117700_bib112","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/jacs.9b12718","article-title":"Optical control of small molecule-induced protein degradation","volume":"142","author":"Naro","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117700_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay5064","article-title":"PHOTACs enable optical control of protein degradation","volume":"6","author":"Reynders","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2025.117700_bib114","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1021\/acs.jmedchem.9b02058","article-title":"Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown","volume":"63","author":"Jin","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib115","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/cmdc.201800271","article-title":"Efficient synthesis of immunomodulatory drug analogues enables exploration of structure\u2013degradation relationships","volume":"13","author":"Burslem","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117700_bib116","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1039\/D2MD00347C","article-title":"Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives","volume":"14","author":"Nowak","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib117","doi-asserted-by":"crossref","first-page":"E1471","DOI":"10.1073\/pnas.1417832112","article-title":"Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs","volume":"112","author":"Jacques","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2025.117700_bib118","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1021\/ol401705a","article-title":"Synthesis and stability of oxetane analogs of thalidomide and lenalidomide","volume":"15","author":"Burkhard","year":"2013","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2025.117700_bib119","doi-asserted-by":"crossref","first-page":"14513","DOI":"10.1021\/acs.jmedchem.3c00851","article-title":"Leveraging ligand affinity and properties: discovery of novel benzamide-type cereblon binders for the design of PROTACs","volume":"66","author":"Steinebach","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib120","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.bmcl.2010.12.031","article-title":"Design, synthesis and biological evaluation of new thalidomide analogues as TNF-\u03b1 and IL-6 production inhibitors","volume":"21","author":"Chaulet","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117700_bib121","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202319856","article-title":"Simplifying access to targeted protein degraders via nickel electrocatalytic cross\u2010coupling","volume":"63","author":"Neigenfind","year":"2024","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.ejmech.2025.117700_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104010","article-title":"Strengthening molecular glues: design strategies for improving thalidomide analogs as cereblon effectors and anticancer agents","author":"Nutt","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.117700_bib123","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the role of linker design in proteolysis targeting chimeras: miniperspective","volume":"64","author":"Bemis","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib124","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1039\/C0MB00074D","article-title":"Impact of linker length on the activity of PROTACs","volume":"7","author":"Cyrus","year":"2011","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.ejmech.2025.117700_bib125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cbpa.2018.05.010","article-title":"Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space","volume":"44","author":"Poongavanam","year":"2018","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117700_bib126","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1039\/C9MD00272C","article-title":"Developing degraders: principles and perspectives on design and chemical space","volume":"10","author":"Maple","year":"2019","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2025.117700_bib127","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","article-title":"Physicochemical property determinants of oral absorption for PROTAC protein degraders","volume":"66","author":"Hornberger","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib128","doi-asserted-by":"crossref","first-page":"12639","DOI":"10.1021\/acs.jmedchem.2c00201","article-title":"Designing soluble PROTACs: strategies and preliminary guidelines","volume":"65","author":"Garc\u00eda Jim\u00e9nez","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117700_bib130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer","volume":"62","author":"Han","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib131","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1021\/acs.jmedchem.3c00405","article-title":"Discovery of ARD-2051 as a potent and orally efficacious proteolysis targeting chimera (PROTAC) degrader of androgen receptor for the treatment of advanced prostate cancer","volume":"66","author":"Han","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib132","first-page":"OF1","article-title":"Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis TArgeting chimera androgen receptor degrader","author":"Snyder","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.117700_bib133","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117700_bib134","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of Bruton's tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib135","doi-asserted-by":"crossref","DOI":"10.1039\/D4MD00769G","article-title":"Property-based optimisation of PROTACs","author":"Scott","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2023.1098331","article-title":"E3 ligase ligand optimization of clinical PROTACs","volume":"11","author":"Jiang","year":"2023","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib137","article-title":"Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy","volume":"3","author":"Han","year":"2022","journal-title":"Cell Rep. Phys. Sci."},{"key":"10.1016\/j.ejmech.2025.117700_bib138","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41573-023-00652-2","article-title":"Delivering on the promise of protein degraders","volume":"22","author":"O'Brien Laramy","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117700_bib139","first-page":"OF1","article-title":"A phase I study of FHD-609, a Heterobifunctional degrader of bromodomain-containing protein 9, in patients with advanced synovial sarcoma or SMARCB1-deficient tumors","author":"Livingston","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117700_bib140","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-ND05","article-title":"Abstract ND05: the discovery of ARV-393, a potent, orally bioavailable BCL6 targeting PROTAC\u00ae for the treatment of non-hodgkin\u2019s lymphoma","volume":"84","author":"Sherman","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117700_bib141","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1182\/blood-2024-208356","article-title":"Phase 1 study of ARV-393, a PROTAC BCL6 degrader, in advanced non-hodgkin lymphoma","volume":"144","author":"Caimi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117700_bib142","doi-asserted-by":"crossref","first-page":"7","DOI":"10.54254\/2753-8818\/15\/20240381","article-title":"Revitalizing thalidomide: advancements in drug design and therapeutic strategies","volume":"15","author":"Yu","year":"2023","journal-title":"Theor. Nat. Sci."},{"key":"10.1016\/j.ejmech.2025.117700_bib143","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/bdd.750","article-title":"Diverse approaches for the enhancement of oral drug bioavailability, biopharm","volume":"32","author":"Fasinu","year":"2011","journal-title":"Drug Dispos."},{"key":"10.1016\/j.ejmech.2025.117700_bib144","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2025.117700_bib145","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3390\/cancers15030963","article-title":"Lenalidomide in multiple myeloma: review of resistance mechanisms, current treatment strategies and future perspectives","volume":"15","author":"Kulig","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117700_bib146","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.molmed.2017.02.006","article-title":"A brighter side to thalidomide: its potential use in immunological disorders","volume":"23","author":"Millrine","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2025.117700_bib147","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98538-z","article-title":"Immunomodulatory effects of thalidomide in an experimental brain death liver donor model","volume":"11","author":"Santana","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117700_bib148","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1286-4579(02)01645-3","article-title":"Thalidomide in the treatment of leprosy","volume":"4","author":"Teo","year":"2002","journal-title":"Microb. Infect."},{"key":"10.1016\/j.ejmech.2025.117700_bib149","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1038\/onc.2012.599","article-title":"Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy","volume":"32","author":"Shortt","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117700_bib150","first-page":"5251","article-title":"Thalidomide and its analogues: a review of the potential for immunomodulation of fibrosis diseases and opthalmopathy","volume":"14","author":"Liu","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejmech.2025.117700_bib151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.55782\/ane-2004-1486","article-title":"Thalidomide-based TNF-\u03b1 inhibitors for neurodegenerative diseases","volume":"64","author":"Greig","year":"2004","journal-title":"Acta Neurobiol. Exp."},{"key":"10.1016\/j.ejmech.2025.117700_bib152","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1021\/acsptsci.1c00042","article-title":"N-adamantyl phthalimidine: a new thalidomide-like drug that lacks cereblon binding and mitigates neuronal and synaptic loss, neuroinflammation, and behavioral deficits in traumatic brain injury and lps challenge","volume":"4","author":"Hsueh","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2025.117700_bib153","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.656921","article-title":"Repurposing immunomodulatory imide Drugs (IMiDs) in neuropsychiatric and neurodegenerative disorders","volume":"15","author":"Jung","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2025.117700_bib154","first-page":"747","article-title":"A new generation of imids as treatments for neuroinflammatory and neurodegenerative disorders","volume":"13","author":"Kopp","year":"2023","journal-title":"Biomol"},{"key":"10.1016\/j.ejmech.2025.117700_bib155","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon\u2013DDB1\u2013lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117700_bib156","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/onc.2012.139","article-title":"Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion","volume":"32","author":"Wei","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117700_bib157","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117700_bib158","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.941742","article-title":"Lenalidomide induces degradation of IKZF1 and IKZF3","volume":"3","author":"Kr\u00f6nke","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejmech.2025.117700_bib159","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41571-021-00479-z","article-title":"Cancer therapies based on targeted protein degradation\u2014lessons learned with lenalidomide","volume":"18","author":"Jan","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117700_bib160","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117700_bib161","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117700_bib162","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117700_bib163","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood.V120.21.905.905","article-title":"Phase II multicenter study of single-agent lenalidomide in subjects with mantle cell lymphoma who relapsed or progressed after or were refractory to bortezomib: the MCL-001 \u201cEMERGE\u201d study","volume":"120","author":"Goy","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117700_bib164","series-title":"Semin. Oncol.","first-page":"223","article-title":"Kaposi sarcoma\u2013associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatment","author":"Bhutani","year":"2015"},{"key":"10.1016\/j.ejmech.2025.117700_bib165","series-title":"Silver Spring, MD","article-title":"FDA grants accelerated approval to pomalidomide for Kaposi sarcoma","author":"Food","year":"2020"},{"key":"10.1016\/j.ejmech.2025.117700_bib166","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1200\/JCO.2016.69.3812","article-title":"Pomalidomide for symptomatic Kaposi's sarcoma in people with and without HIV infection: a phase I\/II study","volume":"34","author":"Polizzotto","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T08:16:39Z","timestamp":1748420199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425004659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":166,"alternative-id":["S0223523425004659"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117700","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthetic approaches to thalidomide based small molecule degraders","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117700"}}